Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H1DV
|
|||
| Former ID |
DNC007988
|
|||
| Drug Name |
N-phenyl-5,6-dip-tolylpyrazine-2-carboxamide
|
|||
| Synonyms |
CHEMBL225242; N-phenyl-5,6-dip-tolylpyrazine-2-carboxamide; SCHEMBL4450848; BDBM35881; 5,6-diaryl-pyrazine-2-amide derivative, 7b; 5,6-di-p-tolyl-pyrazine-2-carboxylic acid phenylamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H21N3O
|
|||
| Canonical SMILES |
CC1=CC=C(C=C1)C2=NC=C(N=C2C3=CC=C(C=C3)C)C(=O)NC4=CC=CC=C4
|
|||
| InChI |
1S/C25H21N3O/c1-17-8-12-19(13-9-17)23-24(20-14-10-18(2)11-15-20)28-22(16-26-23)25(29)27-21-6-4-3-5-7-21/h3-16H,1-2H3,(H,27,29)
|
|||
| InChIKey |
AKCXCZPEESTMSV-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3978-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.